SEC Comment Letter for Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Jul 3, 2019
Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: July 3, 2019 · CIK: 0001596812 · Accession: 0000000000-19-010744
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232413
Letter
July 3, 2019 Shmuel Hess Chief Executive Officer Enlivex Therapeutics Ltd. 14 Einstein Street Nes Ziona Israel 7403618 Re:Enlivex Therapeutics Ltd. Registration Statement on Form F-3 Filed June 28, 2019 File No. 333-232413 Dear Mr. Hess: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Robert L. Grossman, Esq.
Show Raw Text
July 3, 2019
Shmuel Hess
Chief Executive Officer
Enlivex Therapeutics Ltd.
14 Einstein Street
Nes Ziona
Israel 7403618
Re:Enlivex Therapeutics Ltd.
Registration Statement on Form F-3
Filed June 28, 2019
File No. 333-232413
Dear Mr. Hess:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Robert L. Grossman, Esq.